Brief: Simcere Pharmaceutical Resolves To Utilize Repurchase Mandate In Open Market
26/06/2023 15:42
June 26 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* RESOLVED TO UTILIZE REPURCHASE MANDATE IN OPEN MARKET AT
AGGREGATE PRICE OF NOT EXCEEDING RMB500 MILLION
Source text for Eikon: ID:nHKSbPkl3B
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660